FASENRA (Benralizumab) Emerging Drug Insight and Market Forecast - 2032

“FASENRA (Benralizumab) Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about FASENRA (Benralizumab) for Nasal Polyposis in the 7MM. A detailed picture of the FASENRA (Benralizumab) for Nasal Polyposis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the FASENRA (Benralizumab) for Nasal Polyposis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FASENRA (Benralizumab) market forecast, analysis for Nasal Polyposis in the 7MM, descriptive analysis such as SWOT, analyst views comprehensive overview of market competitors, and brief about other emerging therapies in Nasal Polyposis.

Drug Summary

FASENRA (Benralizumab) ),being developed by AstraZeneca, is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). FASENRA targets seven diseases beyond respiratory disease.

Interleukin-5 (IL-5) induces an eosinophil-mediated inflammatory response by binding to the IL-5 receptor (IL-5R) expressed in eosinophils, basophils and some mast cells. Benralizumab, unlike IL-5 low-affinity binding, binds with high affinity to the domain I of the α-chain of IL-5R and blocks its signaling and the proliferation of IL-5-dependent cell lines. On the other hand, benralizumab is an afucosylated antibody in the CH2 region, giving it a high affinity for the FcγRIIIa on natural killer cells, macrophages, and neutrophils; this binding triggers a magnified apoptosis response in eosinophils via antibody-dependent cell-mediated cytotoxicity.

Based on the results of the Ostro and Orchid Phase III trial of FASENRA, AstraZeneca is filling dossiers in the US, EU, Japan, and China. As per the results of the Ostro, FASENRA significantly reduced Nasal Polyp Score (NPS) and average Nasal Blockage Score (NBS) compared with placebo for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP).

FASENRA has an immediate competitor in the same class, i.e., Nucala, the first IL-5 inhibitor approved for nasal polyps developed by GlaxoSmithKline. Except for Nucala, there is Sanofi and Regeneron's Dupixent, another biologic present in the market to give competition to FASENRA.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the FASENRA (Benralizumab) description, mechanism of action, dosage and administration, research and development activities in Nasal Polyposis.
• Elaborated details on FASENRA (Benralizumab) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FASENRA (Benralizumab) research and development activity in Nasal Polyposis details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around FASENRA (Benralizumab).
• The report contains forecasted sales of FASENRA (Benralizumab) for Nasal Polyposis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Nasal Polyposis.
• The report also features the SWOT analysis with analyst views for FASENRA (Benralizumab) in Nasal Polyposis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FASENRA (Benralizumab) Analytical Perspective

In-depth FASENRA (Benralizumab) Market Assessment

This report provides a detailed market assessment of FASENRA (Benralizumab) in Nasal Polyposis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

FASENRA (Benralizumab) Clinical Assessment

The report provides the clinical trials information of FASENRA (Benralizumab) in Nasal Polyposis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Nasal Polyposis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FASENRA (Benralizumab) dominance.
• Other emerging products for Nasal Polyposis are expected to give tough market competition to FASENRA (Benralizumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FASENRA (Benralizumab) in Nasal Polyposis.
• This in-depth analysis of the forecasted sales data of FASENRA (Benralizumab) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FASENRA (Benralizumab) in Nasal Polyposis.

 

Key Questions

• What is the product type, route of administration and mechanism of action of FASENRA (Benralizumab)?
• What is the clinical trial status of the study related to FASENRA (Benralizumab) in Nasal Polyposis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FASENRA (Benralizumab) development?
• What are the key designations that have been granted to FASENRA (Benralizumab) for Nasal Polyposis?
• What is the forecasted market scenario of FASENRA (Benralizumab) for Nasal Polyposis?
• What are the forecasted sales of FASENRA (Benralizumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Nasal Polyposis and how are they giving competition to FASENRA (Benralizumab) for Nasal Polyposis?
• Which are the late-stage emerging therapies under development for the treatment of Nasal Polyposis?

This product will be delivered within 2 business days.